STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced
that a jury trial that had been ongoing since December 4, 2024,
against Isomedix Operations, Inc. (“Isomedix”), a subsidiary of the
Company, ended in a mistrial on January 17, 2025.
The case is pending in the Circuit Court of Cook County,
Illinois, and involves claims by an individual plaintiff that
ethylene oxide emissions from a sterilization facility in Waukegan,
Illinois, caused personal injury. Isomedix owned and operated the
facility from 2005 to 2008.
The Court declared a mistrial at Plaintiff’s request during jury
deliberations when dismissal of one of the jurors reduced the jury
to fewer than twelve. The Court will schedule the case for re-trial
at a later date.
Isomedix intends to continue to vigorously defend against
allegations regarding ethylene oxide operations and emissions from
the Waukegan, Illinois facility during 2005 to 2008. Deploying its
own rigorous best practices, Isomedix has regularly invested in its
facilities and has created processes and procedures that meet or
exceed the applicable environmental regulatory standards.
About STERIS STERIS is a leading global
provider of products and services that support patient care with an
emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A
HEALTHIER AND SAFER WORLD by providing innovative healthcare and
life sciences products and services. For more information, visit
www.steris.com.
Company Contact: Julie Winter, Vice President,
Investor Relations and Corporate
CommunicationsJulie_Winter@steris.com
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATIONThis release may contain statements concerning
certain trends, expectations, forecasts, estimates, or other
forward-looking information affecting or relating to STERIS or its
industry, products or activities that are intended to qualify for
the protections afforded “forward-looking statements” under the
Private Securities Litigation Reform Act of 1995 and other laws and
regulations. Forward-looking statements speak only as to the date
the statement is made and may be identified by the use of
forward-looking terms such as “may,” “will,” “expects,” “believes,”
“anticipates,” “plans,” “estimates,” “projects,” “targets,”
“forecasts,” “outlook,” “impact,” “potential,” “confidence,”
“improve,” “optimistic,” “deliver,” “orders,” “backlog,”
“comfortable,” “trend,” and “seeks,” or the negative of such terms
or other variations on such terms or comparable terminology. Many
important factors could cause actual results to differ materially
from those in the forward-looking statements including, without
limitation, statements related to the expected benefits of and
timing of completion of the Restructuring Plan, disruption of
production or supplies, changes in market conditions, political
events, pending or future claims or litigation, competitive
factors, technology advances, actions of regulatory agencies, and
changes in laws, government regulations, labeling or product
approvals or the application or interpretation thereof. Many of
these important factors are outside of STERIS’s control. No
assurances can be provided as to any result or the timing of any
outcome regarding matters described in STERIS’s securities filings
or otherwise with respect to any regulatory action, administrative
proceedings, government investigations, litigation, warning
letters, cost reductions, business strategies, earnings or revenue
trends or future financial results. References to products are
summaries only and should not be considered the specific terms of
the product clearance or literature. Unless legally required,
STERIS does not undertake to update or revise any forward-looking
statements even if events make clear that any projected results,
express or implied, will not be realized. Other potential risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements include, without
limitation, (a) the impact of public health crises on STERIS’s
operations, supply chain, material and labor costs, performance,
results, prospects, or value, (b) STERIS's ability to achieve the
expected benefits regarding the accounting and tax treatments of
the redomiciliation to Ireland, (c) operating costs, Customer loss
and business disruption (including, without limitation,
difficulties in maintaining relationships with employees,
Customers, clients or suppliers) being greater than expected, (d)
STERIS’s ability to successfully integrate acquired businesses into
its existing businesses, including unknown or inestimable
liabilities, impairments, or increases in expected integration
costs or difficulties in connection with the integration of such
businesses, (e) uncertainties related to tax treatments under the
TCJA and the IRA, (f) the possibility that Pillar Two Model Rules
could increase tax uncertainty and adversely impact STERIS's
provision for income taxes and effective tax rate and subject
STERIS to additional income tax in jurisdictions who adopt Pillar
Two Model Rules, (g) STERIS's ability to continue to qualify for
benefits under certain income tax treaties in light of ratification
of more strict income tax treaty rules (through the MLI) in many
jurisdictions where STERIS has operations, (h) changes in tax laws
or interpretations that could increase our consolidated tax
liabilities, including changes in tax laws that would result in
STERIS being treated as a domestic corporation for United States
federal tax purposes, (i) the potential for increased pressure on
pricing or costs that leads to erosion of profit margins, including
as a result of inflation, (j) the possibility that market demand
will not develop for new technologies, products or applications or
services, or business initiatives will take longer, cost more or
produce lower benefits than anticipated, (k) the possibility that
application of or compliance with laws, court rulings,
certifications, regulations, or regulatory actions, including
without limitation any of the same relating to FDA, EPA or other
regulatory authorities, government investigations, the outcome of
any pending or threatened FDA, EPA or other regulatory warning
notices, actions, requests, inspections or submissions, the outcome
of any pending or threatened litigation brought by private parties,
including the Isomedix litigation, or other requirements or
standards may delay, limit or prevent new product or service
introductions, affect the production, supply and/or marketing of
existing products or services, result in costs to STERIS that may
not be covered by insurance, or otherwise affect STERIS’s
performance, results, prospects or value, (l) the potential of
international unrest, including the Russia-Ukraine or Israel-Hamas
military conflicts, economic downturn or effects of currencies, tax
assessments, tariffs and/or other trade barriers, adjustments or
anticipated rates, raw material costs or availability, benefit or
retirement plan costs, or other regulatory compliance costs, (m)
the possibility of reduced demand, or reductions in the rate of
growth in demand, for STERIS’s products and services, (n) the
possibility of delays in receipt of orders, order cancellations, or
delays in the manufacture or shipment of ordered products, due to
supply chain issues or otherwise, or in the provision of services,
(o) the possibility that anticipated growth, cost savings, new
product acceptance, performance or approvals, or other results may
not be achieved, or that transition, labor, competition, timing,
execution, impairments, regulatory, governmental, or other issues
or risks associated with STERIS’s businesses, industry or
initiatives including, without limitation, those matters described
in STERIS's various securities filings, may adversely impact
STERIS’s performance, results, prospects or value, (p) the impact
on STERIS and its operations, or tax liabilities, of Brexit or the
exit of other member countries from the EU, and the Company’s
ability to respond to such impacts, (q) the impact on STERIS and
its operations of any legislation, regulations or orders, including
but not limited to any new trade or tax legislation (including CAMT
and excise tax on stock buybacks), regulations or orders, that may
be implemented by the U.S. administration or Congress, or of any
responses thereto, (r) the possibility that anticipated financial
results or benefits of recent acquisitions, of STERIS’s
restructuring efforts, or of recent divestitures, including
anticipated revenue, productivity improvement, cost savings, growth
synergies and other anticipated benefits, will not be realized or
will be other than anticipated, (s) the level of STERIS’s
indebtedness limiting financial flexibility or increasing future
borrowing costs, (t) rating agency actions or other occurrences
that could affect STERIS’s existing debt or future ability to
borrow funds at rates favorable to STERIS or at all, (u) the
effects of changes in credit availability and pricing, as well as
the ability of STERIS’s Customers and suppliers to adequately
access the credit markets, on favorable terms or at all, when
needed, and (v) the possibility that our expectations about the
pre-tax savings resulting from the Restructuring Plan, the number
of positions eliminated pursuant to the Restructuring Plan and the
costs, charges and cash expenditures associated with the announced
restructuring plan may not be realized on the timeline or timelines
we expect, or at all.
Grafico Azioni STERIS (NYSE:STE)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni STERIS (NYSE:STE)
Storico
Da Feb 2024 a Feb 2025